Neuigkeiten — Airna

Für Interviewanfragen oder andere Medienanfragen senden Sie bitte eine E-Mail an unser Kommunikationsteam unter media@airna.com.

Pressemitteilungen

12 Mai 2026

AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT

– AIR-001 demonstrated best-in-class potential, achieving up to 59% precise RNA editing in vivo and restoring 40 µM functional M-AAT in a mouse model of AATD – Preclinical data show RNA editing can introduce protective variants for cardiovascular disease and drive reduction of LDL cholesterol levels CAMBRIDGE, Mass., May 12, 2026 – AIRNA, a biotech […]

Lesen

28 April 2026

AIRNA to Present New Preclinical Data on RNA-Editing Therapeutic Pipeline at ASGCT Annual Meeting

CAMBRIDGE, Mass., April 28, 2026 – AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, will present new preclinical data from the company’s pipeline of RNA-editing therapeutics, including lead candidate AIR-001 and the company’s cardiometabolic portfolio, at the 2026 Annual Meeting of the American Society of […]

Lesen

In den Nachrichten

In the News

GEN Edge

31 Juli 2024

RNA Editing Therapy Developer Closes $60M Series A Financing

Ansehen

In the News

BioPharma Dive

31 Juli 2024

Biotech Airna raises $60M for RNA editing medicines

Ansehen

Laura S Pfeiffer, Thorsten Stafforst. doi: 10.1038/s41587-023-01927-0.

Ansehen

Publications

Nature Biotechnology

28 Januar 2019

Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides

Merkle T, Merz S, Reautschnig P, Blaha A, Li Q, Vogel P, Wettengel J, Li JB, Stafforst T. Nat Biotechnol 2019, 37:133-138, doi: 10.1038/s41587-019-0013-6, PMID: 30692694.

Ansehen

Publications

Nucleic Acids Research

29 August 2017